In a trial, Gossamer Bio's PAH treatment candidate seralutinib reduced the resistance blood faces moving into the lungs over ...
Seropositive rheumatoid arthritis may be protective against the development of PAH, based on results of Mendelian randomization analyses.
Gossamer Bio Inc. has released new data showing its inhaled kinase inhibitor, seralutinib, has long-lasting effects on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback